Stem cell therapy for type 1 diabetes: a scientometric assessment of global research during the twenty-first century

Devi Dayal; Brij Mohan Gupta; Ghouse Modin Mamdapur; Latika Rohilla; Pamali Mahasweta Nanda

doi:10.1007/s40200-022-01120-1

Stem cell therapy for type 1 diabetes: a scientometric assessment of global research during the twenty-first century

J Diabetes Metab Disord. 2022 Sep 12;21(2):1679-1687. doi: 10.1007/s40200-022-01120-1. eCollection 2022 Dec.

Authors

Devi Dayal¹, Brij Mohan Gupta², Ghouse Modin Mamdapur³, Latika Rohilla⁴, Pamali Mahasweta Nanda⁴

Affiliations

¹ Endocrinology and Diabetes Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012 India.
² CSIR-National Institute of Science, Technology and Development Studies, New Delhi, India.
³ Information & Documentation, Synthite Industries (Pvt.) Ltd, Kolenchery, Kerala India.
⁴ Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Abstract

Purpose: We aimed to provide a scientometric assessment of global research in stem cell therapy (SCT) for type 1 diabetes (T1D) during 1999-2020.

Methods: The published data on SCT in T1D were retrieved from Elsevier's Scopus database and analyzed using select bibliometric tools. We used VOSviewer software and the Biblioshiny app to construct and visualize bibliometric networks.

Results: The global yield totaled 1806 publications in the 22-year study period, registering a 17.7% annual growth peaking at 196.9% in the last 11 years. The average citations per publication (CPP) decreased from 62.0 during 1999-2009 to 24.3 during 2010-2020. The funded publications were 727 (40.2%). Randomized controlled trials (RCTs) were only 2.4% (45). Amongst 70 participating countries, the USA led with a 38.6% share. Of the 388 global organizations, Harvard Medical School, USA, San Raffaele Scientific Institute, Italy, and the University of Florida, USA were the topmost contributors. Florina, Couri, and Trucco were the top productive authors, whereas Melton, Abdi, and Simoes were the most impactful. Only 129 (3.1%) publications were highly-cited; their total and average CPP were 31,228 and 214.0 (range 101-1841), respectively.

Conclusions: The quantity of research in SCT for T1D has increased during the last two decades while the quality has dipped. The research landscape is dominated by high-income North-American and Western-European countries. There is a need for conducting large-scale RCTs and promoting research collaborations between high- and low-income countries for long-term sustainability and global impact.

Keywords: Bibliometrics; Global publications; Scientometrics; Stem cell therapy; Treatment; Type 1 diabetes.

© The Author(s), under exclusive licence to Tehran University of Medical Sciences 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.